Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by Quattro74on Aug 12, 2020 12:48pm

236 Views

Post# 31398694

RE:RE:RE:RE:RE:RE:Keep Your Eyes On The Numbers...

Hempdoc wrote: That was great news & long overdue. And sorry for the misstatement last night (past my bedtime)...corrections in bold/underlined print...

Just to be clear, there are currently 3 of 7 who would be considered "cancer-free" based on the CR definition:

Negative cystoscopy and negative (including atypical) urine cytology.

Positive cystoscopy with biopsy-proven benign lesions or low-grade NMIBC (unchanged or worsening CIS "not" included) and negative cytology.

Negative cystoscopy with malignant urine cytology, if cancer is found in the upper tract or prostatic urethra and random bladder biopsies are negative.

An additional 3 of 7 are still to be determined. These 3 had negative cystoscopies, but had positive or suspicious cytologies, & hence are awaiting repeat urine cytology. If all are found to be negative on repeat urine testing, they would all be considered a CR (cancer-free). If repeat urine cytology is positive or suspicious, then further confirmatory testing would be needed to rule out upper tract cancer (I.e in kidney/ureter) or lower tract cancer (I.e. in prostatic region). When one has a negative bladder cystoscopy with a repeat urine cytology that is positive & confirmatory testing demonstrates cancer in the upper or lower tract (outside of the bladder), this would also be considered a CR. If there is no cancer noted outside of the bladder, a positive result on "repeat" cytology would "not" be considered a CR.

For the 1 patient of 7 that had a suspicious cystoscopy & negative urine cytology, a confirmatory bladder biopsy that demonstrates either a benign lesion, low-grade NMIBC or unchanged/worsening CIS would be considered a "response" & therefore eligible for a 2nd treatment. Any confirmatory biopsy or CT scan showing NMIBC progression (that is progression to metastatic disease or progression to MIBC) would "not" be considered a response & therefore "not" eligible for a 2nd treatment.